Nevertheless, our study emphasizes the importance of both the gene and metabolite doses in their roles in cancer, and identifies SIRT4 as an oncogene that might be targeted by small molecule inhibitors, antisense oligonucleotides, etc. for the treatment of HCC. This evidence concerns the gene SIRT4 and hepatocellular carcinoma.